Company intelligence / Profile preview

Genemagic Biosciences

Shanghai, Shanghai Shi, China

Ownership: Private
Development stage: Preclinical

Overview

Genemagic Biosciences develops regenerative therapies using in vivo cellular reprogramming and neuroprotection platforms, aiming to treat neuronal loss-related diseases such as Parkinson's. Their lead candidate, GM101-PD—an AAV-based gene therapy that converts striatal astrocytes into dopamine neurons—has shown robust preclinical efficacy and independent third-party validation. The company has additional preclinical/discovery programs targeting glaucoma and stroke. No clinical results are available yet; the most advanced asset has entered clinical trial preparation.

Therapeutic areas: OphthalmologyNeurology
Modalities: AAV-based gene therapyIn vivo cell reprogrammingNeuroprotection techniques
Industry: Biotech

Drug pipeline

1 asset

GM101

Unknown

Beyond the preview

Go deeper on Genemagic Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genemagic Biosciences.

Explore the full profile